June 22, 2024
Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market

Fueling The Growth Of Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics With Rising Cancer Incidences

Cancer Chemotherapy Associated Nausea and Vomiting (CINV) occurs as a side effect of cancer chemotherapy treatment. Chemotherapy is one of the prominent cancer treatment options that uses drugs or a combination of drugs to destroy cancer cells. During chemotherapy treatment, the administered drugs enter the bloodstream and reach all cells and tissues in the body including healthy cells. This often leads to side effects of nausea and vomiting. CINV therapeutics are used to prevent and control nausea and vomiting which are highly distressing to cancer patients undergoing chemotherapy.

The global cancer chemotherapy-associated nausea and vomiting therapeutics market comprises drugs from various classes targeting different pathways involved in the causation of CINV. 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists, and corticosteroids are the commonly used drug classes for CINV prevention and control. These drugs help in blocking receptor activation in the vomiting center and reduce neurotransmitter release which causes nausea and vomiting. The use of multi-drug CINV regimens containing drugs from two or more classes has significantly improved CINV control.

The global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market is estimated to be valued at US$ 3537.91 Mn  in 2024 and is expected to exhibit a CAGR of 5.3%  over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends

Rising incidence of cancer cases globally is one of the key factors driving the growth of cancer chemotherapy associated nausea and vomiting therapeutics market. According to WHO, cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2020. In addition, changing lifestyle habits such as physical inactivity, consumption of processed foods and tobacco usage has led to surge in cancer cases over the years. Strict patient adherence to CINV drug regimens and development of more efficacious drugs with novel mechanisms of action are important trends being observed in the market. Companies are engaged in developing more potent oral therapies with fewer side effects to address unmet needs of moderate to severe CINV cases.

Porter’s Analysis

Threat of new entrants: Low, The Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics market requires high investments in R&D for drug development and manufacturing. Stringent regulations additionally pose a barrier to new players’ entry.

Bargaining power of buyers: Moderate, Several pharma companies provide options for nausea and vomiting treatments giving buyers some negotiating power and choice.

Bargaining power of suppliers: Moderate, Suppliers of active ingredients and contract manufacturing organizations pose moderate bargaining power due availability of alternatives.

Threat of new substitutes: Low, Currently available products have strong brand recognition limiting threat from substitutes.

Competitive rivalry: High, presence of many international and domestic players intensifies competition. Players focus on drug innovations and expanding their geographical presence to sustain competition.

Key Takeaways

The global Cancer Chemotherapy Associated Nausea And Vomiting Therapeutics Market Size is expected to witness high growth over the forecast period of 2024 to 2031. The global Cancer Chemotherapy Associated Nausea and Vomiting Therapeutics Market is estimated to be valued at US$ 3537.91 Mn in 2024 and is expected to exhibit a CAGR of 5.3%  over the forecast period 2024 to 2031.

Regional analysis: North America holds the largest share currently owing to advanced healthcare infrastructure and supportive reimbursement policies in countries like the US and Canada. Asia Pacific is expected to showcase fastest growth potential with growing cancer incidence and improving access to healthcare in countries like China and India.

Key players: Key players operating in the Cancer chemotherapy-associated nausea and Vomiting Therapeutics market are Nature Essential Foods Pvt Ltd, Lotus Bakeries, General Mills Inc., Clif Bar & Company, ProBar LLC, Post Holdings Inc., BumbleBar Inc., PepsiCo Inc., Eat Anytime, TORQ Limited, OTE Sports Ltd, Kind LLC, Science in Sports PLC, and Kellogg Company. Companies are focusing on new product launches and achieving strong geographic presence especially in developing regions to strengthen their market position.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it